TY - JOUR
T1 - Oenothera rosea L´Hér. ex Ait attenuates acute colonic inflammation in TNBS-induced colitis model in rats
T2 - in vivo and in silico myeloperoxidase role
AU - Calva-Candelaria, Natalia
AU - Meléndez-Camargo, María Estela
AU - Montellano-Rosales, Hortensia
AU - Estrada-Pérez, Alan R.
AU - Rosales-Hernández, Martha C.
AU - Fragoso-Vázquez, M. Jonathan
AU - Martínez-Archundia, Marlet
AU - Correa-Basurto, José
AU - Márquez-Flores, Yazmín K.
N1 - Publisher Copyright:
© 2018 Elsevier Masson SAS
PY - 2018/12
Y1 - 2018/12
N2 - Oenothera rosea L´Hér. ex Ait is a species traditionally used in the treatment of inflammation, headache, stomach pain, infections, among others. The aim of this study was evaluating the acute anti-inflammatory activity of the aqueous extract of O. rosea by 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. Rats were randomized into six groups: (I) Sham; (II) EtOH; (III) TNBS; and (IV–VI) 250, 500 and 750 mg/Kg, respectively. The colonic injury was induced (groups III–VI) by intrarectal instillation of 0.25 mL of TNBS (10 mg) in 50% ethanol. Groups I and II received an enema (0.25 mL) of physiological saline solution or 50% ethanol, respectively. Treatments were administered by oral gavage 48, 24 and 1 h prior, and 24 h after the induction. The inflammatory response was assessed considering the macroscopic and microscopic damage, the serum nitric oxide (NO), the colonic IL-1β levels, and the myeloperoxidase (MPO) activity. Moreover, we performed an LC–MS-based metabolite profiling, and a docking on the MPO. Doses of 500 and 750 mg/Kg showed a protective effect in the TNBS-induced colonic damage. This activity was related to the downregulation of evaluated parameters. Also, considering previous reports, 29 metabolites of 91 detected were selected for the docking, of which Isolimonic acid (29) and Kaempferol 3-(2′′,4′′-diacetylrhamnoside) (10) showed the highest affinity to MPO. The aqueous extract of O. rosea protected the TNBS-induced colonic damage in rats, an effect that could be associated with the presence of polyphenolic compounds, alkaloids, and terpenes; as well as their ability to down-regulate MPO activity.
AB - Oenothera rosea L´Hér. ex Ait is a species traditionally used in the treatment of inflammation, headache, stomach pain, infections, among others. The aim of this study was evaluating the acute anti-inflammatory activity of the aqueous extract of O. rosea by 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. Rats were randomized into six groups: (I) Sham; (II) EtOH; (III) TNBS; and (IV–VI) 250, 500 and 750 mg/Kg, respectively. The colonic injury was induced (groups III–VI) by intrarectal instillation of 0.25 mL of TNBS (10 mg) in 50% ethanol. Groups I and II received an enema (0.25 mL) of physiological saline solution or 50% ethanol, respectively. Treatments were administered by oral gavage 48, 24 and 1 h prior, and 24 h after the induction. The inflammatory response was assessed considering the macroscopic and microscopic damage, the serum nitric oxide (NO), the colonic IL-1β levels, and the myeloperoxidase (MPO) activity. Moreover, we performed an LC–MS-based metabolite profiling, and a docking on the MPO. Doses of 500 and 750 mg/Kg showed a protective effect in the TNBS-induced colonic damage. This activity was related to the downregulation of evaluated parameters. Also, considering previous reports, 29 metabolites of 91 detected were selected for the docking, of which Isolimonic acid (29) and Kaempferol 3-(2′′,4′′-diacetylrhamnoside) (10) showed the highest affinity to MPO. The aqueous extract of O. rosea protected the TNBS-induced colonic damage in rats, an effect that could be associated with the presence of polyphenolic compounds, alkaloids, and terpenes; as well as their ability to down-regulate MPO activity.
KW - Anti-inflammatory
KW - Docking
KW - Inflammatory bowel disease
KW - Myeloperoxidase
KW - Oenothera rosea
KW - TNBS
UR - http://www.scopus.com/inward/record.url?scp=85053807183&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2018.09.081
DO - 10.1016/j.biopha.2018.09.081
M3 - Artículo
C2 - 30372897
AN - SCOPUS:85053807183
SN - 0753-3322
VL - 108
SP - 852
EP - 864
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
ER -